Case Report: The window that closed too soon: lessons from a late CLN2 diagnosis and death of a 9-year-old boy
A class of progressive, autosomal recessive neurodegenerative diseases known as neuronal ceroid lipofuscinoses (NCLs) are brought on by lysosomal protein or enzyme dysfunction. This leads to the pathological buildup of autofluorescent ceroid-lipofuscin in neurons and other tissues. In children and y...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2025.1622185/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850086618460848128 |
|---|---|
| author | Anna Bryzik Dawid Larysz Patrycja Larysz Julia Izabela Karpierz Justyna Paprocka |
| author_facet | Anna Bryzik Dawid Larysz Patrycja Larysz Julia Izabela Karpierz Justyna Paprocka |
| author_sort | Anna Bryzik |
| collection | DOAJ |
| description | A class of progressive, autosomal recessive neurodegenerative diseases known as neuronal ceroid lipofuscinoses (NCLs) are brought on by lysosomal protein or enzyme dysfunction. This leads to the pathological buildup of autofluorescent ceroid-lipofuscin in neurons and other tissues. In children and young adults, NCLs are the most frequent cause of dementia and neurodegeneration, and epilepsy, psychomotor regression, visual decline, ataxia, and early death are all examples of clinical characteristics which may appear in the disease’s natural course. Cerliponase alfa (known as Brineura) is an enzyme replacement therapy and has become increasingly important in treating CLN2 disease (late-infantile NCL), which is caused by a deficiency of the lysosomal enzyme tripeptidyl peptidase 1 (TPP1). When started early, it can significantly slow the progression of the disease. We describe the course of a boy’s diagnosis and treatment of CLN2 disease, which demonstrates the negative effects of delayed recognition. NCL was not suspected until more than a year after treatment-resistant epilepsy, progressive ataxia, and psychomotor decline appeared, despite early-onset speech delay, developmental variability, and epileptic seizures beginning at age 3. Clear abnormalities were not found by initial imaging or genetic testing. The child’s neurological decline was already severe by the time biochemical and molecular confirmation of CLN2 disease was obtained at the age of 5, and with increasing seizures, loss of motor and cognitive abilities, vision loss, gastrostomy, tracheostomy, and death at 9 years, he progressed according to the natural course of CLN2. Even with repeated medical contact and neurological evaluations, this case highlights the difficulty of diagnosing NCLs and the significant chance of missing the limited therapeutic window. It emphasizes how neurologists and pediatricians need to be more aware of NCLs as possible causes of developmental regression and early-onset epilepsy. Children with such presentations may benefit from earlier metabolic or enzyme testing, which could increase access to treatments that prolong life and change the disease’s deadly course. |
| format | Article |
| id | doaj-art-5b7b30778cda4696b35fce65be06476d |
| institution | DOAJ |
| issn | 1664-8021 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj-art-5b7b30778cda4696b35fce65be06476d2025-08-20T02:43:25ZengFrontiers Media S.A.Frontiers in Genetics1664-80212025-07-011610.3389/fgene.2025.16221851622185Case Report: The window that closed too soon: lessons from a late CLN2 diagnosis and death of a 9-year-old boyAnna Bryzik0Dawid Larysz1Patrycja Larysz2Julia Izabela Karpierz3Justyna Paprocka4Department of Pediatrics, Haematology and Pediatric Nephrology, Provincial Specialist Hospital, Częstochowa, PolandDepartment of Head and Neck Surgery for Children and Adolescents, Regional Specialized Children’s Hospital Popowski, University of Warmia and Mazury, Olsztyn, PolandDepartment of Head and Neck Surgery for Children and Adolescents, Regional Specialized Children’s Hospital Popowski, University of Warmia and Mazury, Olsztyn, PolandStudents’ Scientific Society, Pediatric Neurology Department, Faculty of Medical Sciences, Medical University of Silesia, Katowice, PolandPediatric Neurology Department, Faculty of Medical Sciences, Medical University of Silesia, Katowice, PolandA class of progressive, autosomal recessive neurodegenerative diseases known as neuronal ceroid lipofuscinoses (NCLs) are brought on by lysosomal protein or enzyme dysfunction. This leads to the pathological buildup of autofluorescent ceroid-lipofuscin in neurons and other tissues. In children and young adults, NCLs are the most frequent cause of dementia and neurodegeneration, and epilepsy, psychomotor regression, visual decline, ataxia, and early death are all examples of clinical characteristics which may appear in the disease’s natural course. Cerliponase alfa (known as Brineura) is an enzyme replacement therapy and has become increasingly important in treating CLN2 disease (late-infantile NCL), which is caused by a deficiency of the lysosomal enzyme tripeptidyl peptidase 1 (TPP1). When started early, it can significantly slow the progression of the disease. We describe the course of a boy’s diagnosis and treatment of CLN2 disease, which demonstrates the negative effects of delayed recognition. NCL was not suspected until more than a year after treatment-resistant epilepsy, progressive ataxia, and psychomotor decline appeared, despite early-onset speech delay, developmental variability, and epileptic seizures beginning at age 3. Clear abnormalities were not found by initial imaging or genetic testing. The child’s neurological decline was already severe by the time biochemical and molecular confirmation of CLN2 disease was obtained at the age of 5, and with increasing seizures, loss of motor and cognitive abilities, vision loss, gastrostomy, tracheostomy, and death at 9 years, he progressed according to the natural course of CLN2. Even with repeated medical contact and neurological evaluations, this case highlights the difficulty of diagnosing NCLs and the significant chance of missing the limited therapeutic window. It emphasizes how neurologists and pediatricians need to be more aware of NCLs as possible causes of developmental regression and early-onset epilepsy. Children with such presentations may benefit from earlier metabolic or enzyme testing, which could increase access to treatments that prolong life and change the disease’s deadly course.https://www.frontiersin.org/articles/10.3389/fgene.2025.1622185/fullneuronal ceroidlipofuscinosisbatten diseaseneurodegenerative diseaseepilepsyrare disease |
| spellingShingle | Anna Bryzik Dawid Larysz Patrycja Larysz Julia Izabela Karpierz Justyna Paprocka Case Report: The window that closed too soon: lessons from a late CLN2 diagnosis and death of a 9-year-old boy Frontiers in Genetics neuronal ceroidlipofuscinosis batten disease neurodegenerative disease epilepsy rare disease |
| title | Case Report: The window that closed too soon: lessons from a late CLN2 diagnosis and death of a 9-year-old boy |
| title_full | Case Report: The window that closed too soon: lessons from a late CLN2 diagnosis and death of a 9-year-old boy |
| title_fullStr | Case Report: The window that closed too soon: lessons from a late CLN2 diagnosis and death of a 9-year-old boy |
| title_full_unstemmed | Case Report: The window that closed too soon: lessons from a late CLN2 diagnosis and death of a 9-year-old boy |
| title_short | Case Report: The window that closed too soon: lessons from a late CLN2 diagnosis and death of a 9-year-old boy |
| title_sort | case report the window that closed too soon lessons from a late cln2 diagnosis and death of a 9 year old boy |
| topic | neuronal ceroidlipofuscinosis batten disease neurodegenerative disease epilepsy rare disease |
| url | https://www.frontiersin.org/articles/10.3389/fgene.2025.1622185/full |
| work_keys_str_mv | AT annabryzik casereportthewindowthatclosedtoosoonlessonsfromalatecln2diagnosisanddeathofa9yearoldboy AT dawidlarysz casereportthewindowthatclosedtoosoonlessonsfromalatecln2diagnosisanddeathofa9yearoldboy AT patrycjalarysz casereportthewindowthatclosedtoosoonlessonsfromalatecln2diagnosisanddeathofa9yearoldboy AT juliaizabelakarpierz casereportthewindowthatclosedtoosoonlessonsfromalatecln2diagnosisanddeathofa9yearoldboy AT justynapaprocka casereportthewindowthatclosedtoosoonlessonsfromalatecln2diagnosisanddeathofa9yearoldboy |